A Transgenic Mouse Model to Study Ebolaviruses and other Filoviruses

研究埃博拉病毒和其他丝状病毒的转基因小鼠模型

基本信息

  • 批准号:
    10038454
  • 负责人:
  • 金额:
    $ 20.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-22 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Ebola viruses and other members of the filovirus family cause severe and often lethal infections. While some progress has been made in regards to the development of experimental countermeasures and insights into the highly pathogenic nature of these viruses, there are still many more unanswered questions, and further advancement is needed towards the development of pan-filovirus therapeutic agents and vaccines. A significant hurdle to research on filoviruses is the accessibility and cost associated with high-containment, biosafety level- 4 laboratories. To partially alleviate this issue, we previously established a replication-defective Ebola virus based on the Zaire ebolavirus (EBOV) genome. This virus, which lacks the essential viral gene VP30 (termed EBOVΔVP30), is biologically inert and safe to use outside of highly specialized BSL-4 containment. In engineered cell lines that stably express EBOV VP30, the virus becomes replication-competent; thus it is a perfect EBOV surrogate for in vitro research given that EBOVΔVP30 resembles authentic virus in its life cycle, morphology, protein composition, and growth kinetics. After extensive safety testing both in cell culture and in animal models, the CDC and the Office of Science Policy at the NIH classified EBOVΔVP30 as a BSL-2 agent and removed the virus from Select Agent regulations. Since then, this in vitro system to study EBOV has been requested by and distributed to several other research laboratories. The next step to advance the EBOVΔVP30 system is to develop an EBOV VP30 transgenic animal model to support virus replication. Previously, we generated a transgenic mouse line that expressed EBOV VP30 under the control of the chicken beta-actin promoter (CAG). Although we were able to detect VP30 mRNA in key organs, such as the liver, and functional VP30 protein in cells, such as fibroblasts, we were unable to detect VP30 mRNA and functional protein in monocyte-derived macrophages, the first target of EBOV infection and a cell type essential for virus dissemination throughout the body. Here, we propose to generate a new transgenic mouse line with EBOV VP30 expression under the control of the CD45 promoter, a promoter specific for expression in hematopoietic cells, including monocytes, macrophages, and dendritic cells. Once we confirm the expression and function of VP30 in these cell types, particularly macrophages, we will cross our two different VP30 transgenic lines (CAG and CD45) to generate a double knock-in transgenic mouse line. Once established, we will infect these transgenic mice with mouse-adapted EBOVΔVP30 and characterize the phenotype. We will also generate chimeric versions of EBOVΔVP30 with glycoproteins from other filoviruses and examine the phenotype of these chimeric viruses in the transgenic mice. After safety testing, this new small animal model will be an ideal in vivo surrogate for the authentic mouse model for EBOV infection. For the first time, a transgenic mouse model will be available that can be used efficiently and safely outside of BSL-4 containment to examine EBOV pathogenesis and accelerate the development and evaluation of countermeasures.
项目摘要 埃博拉病毒和丝状病毒家族的其他成员会引起严重且通常致命的感染。虽然一些 在制定实验对策和深入了解 尽管这些病毒具有高致病性,但仍有许多问题没有得到解答, 需要朝着开发泛丝状病毒治疗剂和疫苗的方向取得进展。显著 丝状病毒研究的障碍是与高遏制、生物安全水平相关的可及性和成本, 4实验室为了部分缓解这个问题,我们之前建立了一种复制缺陷型埃博拉病毒 扎伊尔埃博拉病毒(EBOV)基因组。这种病毒缺乏必需的病毒基因VP 30(称为VP 30)。 EBOVΔ VP 30)是生物惰性的,在高度专业化的BSL-4容器外使用是安全的。在 在稳定表达EBOV VP 30的工程化细胞系中,病毒变得具有复制能力;因此,它是一种 EBOVΔ VP 30在其生命周期中与真实病毒相似, 形态学、蛋白质组成和生长动力学。经过广泛的安全性测试,无论是在细胞培养, 在动物模型中,CDC和NIH的科学政策办公室将EBOVΔ VP 30归类为BSL-2因子 并将该病毒从特工条例中删除从那时起,这种研究EBOV的体外系统一直是 并分发给其他几个研究实验室。 推进EBOVΔ VP 30系统的下一步是开发EBOV VP 30转基因动物模型, 支持病毒复制。先前,我们在体外培养条件下产生了表达EBOV VP 30的转基因小鼠系。 鸡β-肌动蛋白启动子(CAG)的控制。虽然我们能够在关键的细胞中检测到VP 30 mRNA, 器官,如肝脏,和细胞中的功能性VP 30蛋白,如成纤维细胞,我们无法检测到 EBOV感染的第一靶点--单核细胞源性巨噬细胞中VP 30 mRNA和功能蛋白的研究 病毒在全身传播所必需的细胞类型。在这里,我们建议产生一种新的转基因 具有在CD 45启动子控制下的EBOV VP 30表达的小鼠系,所述启动子特异于 在造血细胞中表达,包括单核细胞、巨噬细胞和树突细胞。一旦我们确认 VP 30在这些细胞类型,特别是巨噬细胞中的表达和功能,我们将交叉我们的两个不同的 VP 30转基因系(CAG和CD 45)以产生双敲入转基因小鼠系。一旦建立, 我们将用小鼠适应的EBOVΔ VP 30感染这些转基因小鼠并表征其表型。我们将 我们还用来自其他丝状病毒的糖蛋白产生EBOVΔ VP 30的嵌合版本,并检查 这些嵌合病毒在转基因小鼠中的表型。经过安全测试,这种新的小动物模型将 是EBOV感染的真实小鼠模型的理想体内替代物。这是第一次,一个转基因 将提供小鼠模型,可在BSL-4防护范围外有效和安全地用于检查 EBOV致病机理及加速评价对策研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOSHIHIRO KAWAOKA其他文献

YOSHIHIRO KAWAOKA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOSHIHIRO KAWAOKA', 18)}}的其他基金

Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
  • 批准号:
    10821572
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
  • 批准号:
    10206685
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
  • 批准号:
    10359831
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
Immunological responses to pan-CoV vaccines
对泛冠状病毒疫苗的免疫反应
  • 批准号:
    10841734
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
COVID-19 comorbidity studies in Syrian hamster models
叙利亚仓鼠模型中的 COVID-19 合并症研究
  • 批准号:
    10450889
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
Administrative core
行政核心
  • 批准号:
    10841732
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
Design and evaluation of pan-CoV vaccines
泛冠状病毒疫苗的设计和评估
  • 批准号:
    10327848
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
Design and evaluation of pan-CoV vaccines
泛冠状病毒疫苗的设计和评估
  • 批准号:
    10841733
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
PanCorVac(泛冠状病毒疫苗开发中心)
  • 批准号:
    10841731
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:
COVID-19 comorbidity studies in Syrian hamster models
叙利亚仓鼠模型中的 COVID-19 合并症研究
  • 批准号:
    10285154
  • 财政年份:
    2021
  • 资助金额:
    $ 20.66万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 20.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了